Replies to post #3683 on ImClone Systems Inc (formerly IMCL)

[jbog]

Bio,

There's a lot of attention being given to the Igfr-1 receptor. The bad news is Pfizer seems to be the most advanced followed by Imclone. The good news is Pfizer based their mab on the xenomouse platform (no adcc).

There are multiple tki's also with Amgen, Bristol and now Biogen playing with it.

It seems the NCI is teaming up with Imclone on theirs.